HemaCare Announces Sale of Coral Blood Services Assets and Reports Six Month Results

Before you go, we thought you'd like these...
Before you go close icon

HemaCare Announces Sale of Coral Blood Services Assets and Reports Six Month Results

LOS ANGELES--(BUSINESS WIRE)-- HemaCare Corporation has completed the sale of its Coral Blood Services subsidiary to the New York Blood Center ("NYBC"). Financial terms of the transaction were not disclosed. Coral's 24 employees have been offered equivalent positions at NYBC.

In addition, NYBC and HemaCare have signed an agreement granting HemaCare access to NYBC's 22 metro New York area collection centers. This allows HemaCare to further support the skilled, standardized apheresis collection services required for cell therapy and immunotherapy clinical trials of HemaCare's rapidly growing list of BioResearch Products and Services customers.

Researchers and product developers require the most consistent, standardized primary human cells, obtained from an FDA-registered, GMP/GTP-compliant collection facility, and processed to purify specific cell populations. HemaCare alone meets this need for extremely consistent, high-quality primary human cells, collected in an FDA-registered facility, in accordance with GMP/GTP requirements. HemaCare's ability to access a growing network of collection centers, established expertise in GMP/GTP apheresis collection, and cell purification capabilities allow the Company to support developers of cell therapy and immunotherapy products from initial preclinical research, to clinical trials, and ultimately commercialization.

Commenting on the transaction, Pete van der Wal, HemaCare's Chief Executive Officer, stated, "Our relationship with NYBC expedites HemaCare's increasing focus on the rapidly growing global cellular and immunotherapy markets. Our budding BioResearch Products and Services division supports researchers and product developers along the entire continuum from preclinical R&D, through Phase I, II, and III clinical trials, to commercialization."

"With our acquisition of Coral Blood Services, we hope to synergize our strengths to better serve our partner hospitals and their patients," said NYBC President and CEO Christopher D. Hillyer, MD. "For the past month, we have been working with Coral to ensure a seamless transition for the hospitals and patients they serve. NYBC looks forward to incorporating the best practices of both organizations to ensure a high quality and customer-focused service for all of our hospitals and patients."

HemaCare also reported its financial results for the six months ended June 30, 2013. For the six month period, revenue rose by 3% to $7.16 million, while the loss from continuing operations increased by 54% to $1,639,000 when compared to the year-earlier period. The results of the operations of Coral Blood Services are reported as discontinued operations on the statement of operations, and as assets held for sale with related liabilities on the balance sheet. (Also included in discontinued operations in 2012 is the liability dismissal write off of HemaCare BioScience in January 2012.) For comparison purposes, the June 30, 2012 statement of operations and the December 31, 2012 balance sheet have been restated for this presentation.

Commenting on the results, van der Wal stated, "First half results were impacted by continuing challenges in our legacy businesses, but we have accelerated our investment into our BioResearch Products and Services division in order to capitalize on the opportunity in this fragmented, but fast-growing, market niche. Given our exceptional combination of core competencies, and with this new significant cash infusion from the Coral sale, we are uniquely positioned to provide our customers a superior value proposition."

(Financial Table Follows)

HemaCare Corporation   Six Months Ended
Condensed Statements of Operations June 30,
  2013     2012


Revenue $ 7,163,000 $ 6,943,000
Gross Profit $ 473,000     $ 1,032,000  
General and administrative expenses $ 2,099,000     $ 2,075,000  
Loss before taxes and discontinued operations ($1,626,000 ) ($1,043,000 )
Provision for income taxes $ 13,000     $ 20,000  
Net loss before discontinued operations ($1,639,000 ) ($1,063,000 )

Income from discontinued operations, net of tax



    $ 2,439,000  
Net (loss) income   ($1,205,000 ) $ 1,376,000  
Basic and diluted (loss) earnings per share   ($0.12 ) $ 0.13  
Weighted average shares outstanding - basic   10,341,519     10,331,519  
Weighted average shares outstanding - diluted   10,341,519     10,341,519  
HemaCare Corporation

Condensed Consolidated Balance Sheets

  6/30/2013   12/31/2012

As Restated

Cash and cash equivalents $ 910,000 $ 1,460,000
Other current assets 3,642,000 3,977,000
Non-current assets   2,321,000   2,547,000
Total assets $ 6,873,000 $ 7,984,000
Liabilities and Shareholders' Equity:
Current liabilities $ 2,300,000 $ 2,178,000
Long-term liabilities 372,000 427,000
Shareholders' equity   4,201,000   5,379,000
Total liabilities and shareholders' equity $ 6,873,000 $ 7,984,000

About HemaCare Corporation

HemaCare Corporation is a leading blood products and services company serving healthcare providers and the scientific community for over 35 years. HemaCare performs therapeutic apheresis services, provides human-derived primary blood cells and tissues for advanced biomedical research, supports cell therapy clinical trials and commercialization with apheresis collections, and provides a wide range of consulting services in SOP development, personnel training, and quality and regulatory compliance.

HemaCare's responsive, cost-effective, GMP/GTP-compliant apheresis collection services leverage our years of experience in apheresis collection, quality systems, fully integrated support infrastructure, and network of FDA-registered collection centers. HemaCare supports industry and academic organizations with apheresis collection services for preclinical research, clinical trials from Phase I through Phase III, and commercial cell therapy applications.

HemaCare's BioResearch Products and Services division specializes in customized collection, isolation and testing of primary human blood cells and other biological products for research protocols. HemaCare's extensive registry of well-characterized repeat donors, and controlled procedures ensure a readily-available inventory of high-quality, consistent primary human cells and biological products for advanced biomedical research.

The Company was founded in 1978 and is based in Van Nuys, California. It trades on the OTC Pink Market under the symbol "HEMA". Website: www.hemacare.com

About New York Blood Center

New York Blood Center (NYBC) is one of the nation's largest non-profit, community-based blood centers. For almost 50 years, NYBC has been providing blood, transfusion products and services to hospitals serving more than 20 million people in New York City, Long Island, the Hudson Valley, New Jersey, and parts of Connecticut and Pennsylvania.

NYBC is also home to the Lindsley F. Kimball Research Institute and the National Cord Blood Program at the Howard P. Milstein National Cord Blood Center, the world's largest public cord blood bank providing stem cells for transplantation.

NYBC provides medical services and programs (Clinical, Transfusion, and Hemophilia Services) through our medical professionals along with consultative services in transfusion medicine. Please visit us on Facebook at www.Facebook.com/newyorkbloodcenter. Follow us on Twitter: @NY_BloodCenter. Website: www.nybloodcenter.org

HemaCare Corporation
Pete van der Wal, Chief Executive Officer

KEYWORDS:   United States  North America  California  New York


The article HemaCare Announces Sale of Coral Blood Services Assets and Reports Six Month Results originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

People are Reading